4.7 Article

COVID-19 vaccines: Global challenges and prospects forum recommendations

Journal

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 105, Issue -, Pages 448-451

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.02.093

Keywords

Vaccine; COVID19; MERS; SARS

Funding

  1. King Abdullah International Medical Research Center [RC15/163]

Ask authors/readers for more resources

The forum discussed the global challenges and prospects of COVID-19 vaccines, highlighting the importance of investing in biotech-pharma to combat future health crises, with a focus on Saudi Arabia's leadership in the field among G20 members.
The 11th KAIMRC Annual Research Forum Themed ?COVID-19 Vaccine: Global Challenges and Prospects Forum? discussed COVID19 Vaccines. The Forum was a vital event as it provided a hub for leading COVID-19 vaccine scientists, regulators, developers, and distributors to learn about COVID-19 vaccines in development, make decisions about the best vaccines to use, and develop appropriate plans for global distribution and pricing. The COVID-19: Global Efforts for Development, Clinical Trials and Distribution Symposium brought together leading scientists, clinicians, pharma, decision makers, academic institutions and businesses to present and discuss the vaccines that are being currently developed for the COVID19. This event was held to shed light on these vaccines as many are at the late stage of Phase III clinical trials and ready to be marketed. This follows the confusion that few vaccines were produced and pushed into phase III without sharing all the necessary data preventing the scientific and clinical community to judge its efficacy and safety. This event allowed a discussion into the challenges in the distribution, pricing and accessibility of the vaccines. Moreover, the symposium discussed the importance to invest in Biotech-Pharma to combat and overcome any future health crisis. The discussion focused on Saudi Arabia leading initiatives as front runner in the field among G20 members. ? 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available